Skip to main content

Advertisement

ADVERTISEMENT

Hemophilia News

News
06/19/2024
Grace Taylor, MS, MA
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy,...
06/19/2024
First Report Managed Care
News
05/24/2024
Jolynn Tumolo
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human coagulation factor VIII, which holds significant importance in managing hemophilia A, is poised for substantial growth over the coming years, according to market research firm Quants and Trends.
The global market for human...
05/24/2024
First Report Managed Care
News
05/09/2024
Jolynn Tumolo
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care

Advertisement

News
04/04/2024
Hannah Musick
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in...
04/04/2024
First Report Managed Care
News
11/10/2023
Jolynn Tumolo
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model...
11/10/2023
First Report Managed Care
News
10/27/2023
Julie Gould
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies...
10/27/2023
First Report Managed Care

Advertisement

News
10/16/2023
Julie Gould
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study published online in Cureus, “Increasing education about existing AHA guidelines, including available therapies and access to expert care at hemophilia treatment centers, may help improve the outcomes of patients...
According to a recent study...
10/16/2023
First Report Managed Care
News
08/09/2023
Hannah Musick
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review discussed the value of emerging gene therapies for patients with hemophilia, emphasizing that one of the biggest challenges remains the appropriate selection of patients.
Authors of a recent review...
08/09/2023
First Report Managed Care
News
07/21/2023
Jolynn Tumolo
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess whether high payments, especially among individuals who have responsibility over the success of hemophilia centers and clinics, may result in competition with the interest of the patients at these centers and...
“Future studies should assess...
07/21/2023
First Report Managed Care

Advertisement

News
07/17/2023
Julie Gould
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping review explored trends in the efficacy and feasibility of implementing pharmacokinetic-guided dosing in clinical practice for patients with bleeding disorders.
Authors of a recent scoping...
07/17/2023
First Report Managed Care

Advertisement